Italy, EU refuse AstraZeneca request to ship 250,000 doses of vaccine to Australia

5 March 2021 - Italy and the European Union have blocked a shipment of the Oxford-AstraZeneca coronavirus vaccine destined for Australia ...

Read more →

Eczema medicine Dupixent added to Pharmaceutical Benefits Scheme

26 February 2021 - Eczema has a significant effect on sufferers’ physical and mental wellbeing, but the new listing of a ...

Read more →

New Zealand Pharmaceutical Schedule - 1 March 2021

1 March 2021 - The March 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

GSK receives CHMP positive opinion recommending approval of dostarlimab for women with recurrent or advanced endometrial cancer

26 February 2021 - GlaxoSmithKline today announced the CHMP of the EMA has adopted a positive opinion recommending dostarlimab, an anti-programmed ...

Read more →

FDA issues emergency use authorisation for third COVID-19 vaccine

27 February 2021 - Action advances fight against COVID-19, follows comprehensive evaluation of available safety, effectiveness and manufacturing quality information by ...

Read more →

FDA approves first treatment for molybdenum cofactor deficiency type A

26 February 2021 - Today, the U.S. FDA approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to ...

Read more →

Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy treatment with proven efficacy in adults, children and infants two months and older

26 February 2021 - Evrysdi is approved in seven countries, submitted in 30 more. ...

Read more →

FDA authorises marketing of novel device to help protect athletes’ brains during head impacts

26 February 2021 - Today, the U.S. FDA authorised marketing of a new device intended to be worn around the neck ...

Read more →

Thousands of breast cancer patients to have routine access to NICE-approved drug combination

26 February 2021 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for ...

Read more →

Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache

25 February 2021 - The first and only anti-CGRP treatment with dual indications. ...

Read more →

BioCryst receives positive CHMP opinion for Orladeyo (berotralstat), an oral, once daily therapy to prevent attacks in patients with hereditary angioedema

25 February 2021 - BioCryst Pharmaceuticals today announced that the CHMP of the EMA has adopted a positive opinion recommending ...

Read more →

Medexus announces expanded availability of Gleolan in Canada

25 February 2021 - Medexus Pharmaceuticals announced today that it has initiated the commercial launch of Gleolan in Canada, which had ...

Read more →

Empirical Spine initiates PMA submission process for FDA approval of Limiflex for degenerative spondylolisthesis

25 February 2021 - The LimiFlex Paraspinous Tension Band is a new, investigational device designed as an alternative to spinal fusion ...

Read more →

Retrotope granted rare paediatric disease designation from FDA for lead development candidate, RT001, in two life-threatening neurodegenerative indications

25 February 2021 - RT001 also granted fast track designation by FDA in Friedreich’s ataxia. ...

Read more →

NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE

25 February 2021 - NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more ...

Read more →

Allergan submits new drug application for investigational AGN-190584 for the treatment of presbyopia

25 February 2021 - If approved, this is expected to be the first eye drop to treat presbyopia. ...

Read more →